ArticleLipids in health and disease2026
Triglyceride-glucose index and anti-Ro52 antibody for identification of cardiovascular disease in patients with primary Sjögren's disease.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPrimary Sjögren's disease (pSjD) confers a markedly elevated risk for developing CVD, an important contributor to mortality in this population. This study was designed to identify factors associated with CVD in pSjD and to develop a classification model.
methodsIn this cross-sectional analysis of pSjD individuals (2013-2023), multivariable logistic regression was used to identify CVD-related factors. A classification model was constructed with variable selection via LASSO regression and the Boruta algorithm.
resultsAmong 734 patients with pSjD, 192 (26.2%) had CVD. Age (odds ratio [OR]: 1.06, P < 0.001), body mass index (BMI; OR: 1.14, P < 0.001), triglyceride-glucose (TyG) index (OR: 3.49, P < 0.001), and positive anti-Ro52 status (OR: 1.58, P = 0.022) were independent correlates of CVD in pSjD. Moreover, age, BMI, and TyG index showed a trend of gradually increasing CVD risk in patients with pSjD (P < 0.05). A five-variable classification model incorporating age, BMI, TyG index, anti-Ro52 antibody, and corrected QT interval was developed to identify CVD status. Good discrimination (area under the curve: 0.768), proper calibration, and clinical applicability were observed for this model. Its performance remained robust upon internal validation and testing in the test set (area under the curve: 0.753 and 0.821).
conclusionThe TyG index and anti-Ro52 antibody serve as significant factors associated with prevalent CVD in patients with pSjD. A novel classification model that integrates these biomarkers with age, BMI, and corrected QT interval showed good performance and generalizability, and may provide a practical tool for identifying cardiovascular status in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.